| Outcome Measures: |
Primary: Absolute change from baseline to end of randomized treatment period in glycosylated hemoglobin A1c (HbA1c) | Secondary: Changes in the following variables from baseline to the end of the randomized treatment period:|The change in fasting plasma glucose (FPG), insulin, proinsulin and C-peptide|Insulin sensitivity by assessment of change in the calculated variable homeostasis assessment model|Lipid parameters (triglyceride [TG], total cholesterol, high-density lipoprotein cholesterol [HDL C], non-HDL C, low-density lipoprotein cholesterol [LDL C], apolipoproteins [Apo] A-I, Apo B, Apo CIII, free fatty acids, lipoprotein particle size and c|C-reactive protein, LDL C/HDL C ratio and Apo B/Apo A-I ratio|FPG, homeostasis assessment model, insulin, proinsulin, C-peptide|Tumor necrosis factor-alpha, intracellular adhesion molecule-1|Fibrinogen|Urinary albumin excretion|Waist/hip ratio|Responder analyses for HbA1c, FPG, TG, HDL C, total cholesterol, non HDL C and LDL C according to pre-specified values|Proportion of patients reaching pre-specified target levels for HbA1c, FPG, TG, HDL C, non-HDL C and LDL C|Pharmacokinetics of tesaglitazar|Safety and tolerability of tesaglitazar by assessment of adverse events, laboratory values, electrocardiogram, pulse, blood pressure, hypoglycemic events, body weight, cardiac evaluation, and physical examination
|
| Locations: |
Research Site, Antwerpen, Belgium|Research Site, Braine-L'alleud, Belgium|Research Site, Hasselt, Belgium|Research Site, Liege, Belgium|Research Site, Merksem, Belgium|Research Site, Sint-Gillis-Waas, Belgium|Research Site, Steenokkerzeel, Belgium|Research Site, Shatin, N.T., Hong Kong|Research Site, Balatonfüred, Hungary|Research Site, Budapest, Hungary|Research Site, Kaposvár, Hungary|Research Site, Kecskemét, Hungary|Research Site, Székesfehérvár, Hungary|Research Site, Arenzano, Italy|Research Site, Chiavari (GE), Italy|Research Site, Chieri, Italy|Research Site, Gubbio (PG), Italy|Research Site, Milano, Italy|Research Site, Napoli, Italy|Research Site, Padova, Italy|Research Site, Perugia, Italy|Research Site, Piacenza, Italy|Research Site, Reggio Calabria, Italy|Research Site, Reggio Emilia, Italy|Research Site, Rho, Italy|Research Site, Roma, Italy|Research Site, Udine, Italy|Research Site, Kubang Kerian, Kota Bharu, Malaysia|Research Site, Kuala Lampur, Malaysia|Research Site, México, D.f., Mexico|Research Site, Guadalajara, Jalisco, Mexico|Research Site, Zapopan, Jalisco, Mexico|Research Site, Veracruz, Mexico|Research Site, Bergen, Norway|Research Site, Kongsvinger, Norway|Research Site, Lysaker, Norway|Research Site, Oslo, Norway|Research Site, Skedsmokorset, Norway|Research Site, Sørumstand, Norway|Research Site, Trondheim, Norway|Research Site, Ås, Norway|Research Site, Manila, Philippines|Research Site, Pasig City, Philippines|Research Site, Kraków, Poland|Research Site, Lublin, Poland|Research Site, P³ock, Poland|Research Site, Toruñ, Poland|Research Site, Tychy, Poland|Research Site, Warszawa, Poland|Research Site, £ód?, Poland|Research Site, Bratislava, Slovakia|Research Site, Ilava, Slovakia|Research Site, Kosice, Slovakia|Research Site, Kysucke Nove Mesto, Slovakia|Research Site, Lubochna, Slovakia|Research Site, Lucenec, Slovakia|Research Site, Nitra, Slovakia|Research Site, Presov, Slovakia|Research Site, Trnava, Slovakia|Research Site, Cape Town, South Africa|Research Site, Durban, South Africa|Research Site, Houghton Gauteng, South Africa|Research Site, Changhua, Taiwan|Research Site, Taichung, Taiwan|Research Site, Taipei, Taiwan|Research Site, Bangkok, Thailand
|
